Bayer Proposes $7.25 Billion Roundup Settlement as Trump Administration Backs Supreme Court Appeal
Key Insights
Bayer has proposed a $7.25 billion class settlement to resolve cancer (search) litigation claims related to its Roundup (search) weedkiller, covering both existing and future cases for up to 21 years.
The Trump administration has urged the U.S. Supreme Court to hear Bayer's case, arguing that federal pesticide regulations should override state-level failure-to-warn lawsuits.
Approximately 65,000 claimants in the United States allege that Roundup (search) caused cancer (search) diagnoses like non-Hodgkin lymphoma (search), despite conflicting assessments from health agencies.
Bayer AG has announced a proposed $7.25 billion class settlement to resolve widespread cancer (search) litigation related to its Roundup (search) weedkiller, while simultaneously receiving crucial support from the Trump administration for its Supreme Court appeal that could fundamentally reshape product liability law.
The comprehensive settlement proposal, announced Tuesday and pending approval in a Missouri state court, aims to address both existing and future claims against the company over a span of up to 21 years. This development comes as Bayer faces approximately 65,000 claimants in the United States who allege that Roundup (search) caused cancer (search) diagnoses, particularly non-Hodgkin lymphoma (search).
Trump Administration Backs Federal Preemption Argument
The Trump administration has urged the U.S. Supreme Court to hear Bayer's case, with Solicitor General D. John Sauer arguing that federal pesticide law should override state-level failure-to-warn lawsuits. This position could potentially limit or shut down thousands of claims seeking compensation in court.
"The support of the U.S. government is an important step and good news for U.S. farmers, who need regulatory clarity," Bayer CEO Bill Anderson stated. "The stakes could not be higher as the misapplication of federal law jeopardizes the availability of innovative tools for farmers and investments in the broader U.S. economy."
Bayer's legal argument centers on the premise that because the EPA decides what goes on a pesticide label, individual states cannot require different warnings. The company contends it cannot be sued for omitting a cancer (search) warning that the federal government never required.
Conflicting Scientific Assessments Drive Litigation
The litigation stems from conflicting assessments by health agencies regarding glyphosate, Roundup (search)'s active ingredient. The International Agency for Research on Cancer (search) has classified glyphosate as "probably carcinogenic to humans," while the U.S. Environmental Protection Agency (search) has determined that the chemical is "not likely to be carcinogenic to humans" when used as directed.
"Glyphosate has been tested and found safe by every major food regulator, safety regulator in the world," Anderson said during an exclusive interview. "If you have hundreds of scientists paid for by taxpayer dollars who determine a product is safe, that has to count for something."
Financial Impact and Market Response
The proposed settlement represents Bayer's latest effort to resolve the massive litigation burden inherited through its 2018 acquisition of Monsanto (search) for $63 billion. The company has already paid billions to resolve previous Roundup (search) claims, with thousands more still pending.
Following the settlement announcement, Bayer's shares saw a notable increase as the company endeavors to rebuild investor trust, which has wavered due to past hefty jury awards against it. The company has been ordered to pay substantial damages in previous cases, including a $2.1 billion award in one of the latest Roundup (search) weedkiller losses.
Supreme Court Decision Could Reshape Liability Landscape
The U.S. Supreme Court's agreement to hear the appeal represents a potentially pivotal moment for Bayer in reducing its future litigation risks. The case could establish important precedent regarding the relationship between federal regulatory approval and state tort liability.
Bayer argues that this is "a really important topic for farmers, for American consumers and, frankly, for food security in America." The company maintains that regulatory clarity is essential for the agricultural sector and broader U.S. economy.
The proposed settlement, if approved, would provide a comprehensive resolution to one of the largest mass tort litigations in recent history, while the Supreme Court case could determine whether similar federal preemption arguments succeed in other product liability contexts.